Centessa Pharmaceuticals Ownership
| CNTA Stock | USD 15.81 0.82 4.93% |
Centessa |
Centessa Stock Ownership Analysis
About 97.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 2.06. Centessa Pharmaceuticals had not issued any dividends in recent years. Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom. Centessa Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 68 people. For more info on Centessa Pharmaceuticals PLC please contact Saurabh MD at 44 203 9206789 or go to https://www.centessa.com.Besides selling stocks to institutional investors, Centessa Pharmaceuticals also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Centessa Pharmaceuticals' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Centessa Pharmaceuticals' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Centessa Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Centessa Pharmaceuticals Insider Trades History
Only 1.29% of Centessa Pharmaceuticals PLC are currently held by insiders. Unlike Centessa Pharmaceuticals' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Centessa Pharmaceuticals' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Centessa Pharmaceuticals' insider trades
Centessa Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Centessa Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Centessa Pharmaceuticals PLC backward and forwards among themselves. Centessa Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Centessa Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Point72 Asset Management, L.p. | 2024-12-31 | 3.4 M | T. Rowe Price Investment Management,inc. | 2024-12-31 | 3.4 M | Siren, L.l.c. | 2024-12-31 | 3 M | Tcg Crossover Management, Llc | 2024-12-31 | 2.9 M | Cormorant Asset Management, Llc | 2024-12-31 | 2.6 M | Franklin Resources Inc | 2024-12-31 | 2.3 M | Commodore Capital Lp | 2024-12-31 | 2.2 M | Octagon Capital Advisors Lp | 2024-12-31 | 2 M | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 1.9 M | Medicxi Ventures Management (jersey) Ltd | 2024-09-30 | 20 M | Index Venture Life Associates Vi Ltd | 2024-12-31 | 10 M |
Centessa Pharmaceuticals Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Centessa Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Centessa Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Centessa Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Centessa Pharmaceuticals Outstanding Bonds
Centessa Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Centessa Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Centessa bonds can be classified according to their maturity, which is the date when Centessa Pharmaceuticals PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Centessa Pharmaceuticals Corporate Filings
8K | 24th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 16th of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Centessa Pharmaceuticals PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Centessa Pharmaceuticals. If investors know Centessa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Centessa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Centessa Pharmaceuticals is measured differently than its book value, which is the value of Centessa that is recorded on the company's balance sheet. Investors also form their own opinion of Centessa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Centessa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Centessa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Centessa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Centessa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Centessa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Centessa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.